Dental implant manufacturer banned from falsely claiming its cut

Dental implant manufacturer banned from falsely claiming its cut-price
implants are hydrophilic

  *German court orders Medentis Medical GmbH ("Medentis") to retract claim
    that its ICX-templant has a hydrophilic surface
  *Tests prove Medentis claim to be spurious

Basel, 26 February 2013 - Straumann has won an important legal battle against
a cut-price implant manufacturer, who misleadingly claimed its dental implants
had a hydrophilic surface. A German court has ruled definitively that Medentis
Medical GmbH (Dernau, Germany) must retract the claim that its ICX-templant
implant is 'hydrophilic'.

Medentis initially contested the injunction, but the Court found the company's
supporting evidence to be unconvincing. In a hearing on 24 January 2013,
Medentis withdrew the appeal and accepted the injunction.

The court's ruling was prompted by Straumann, the leading manufacturer of
hydrophilic implants. Straumann tested the ICX-templant in its own
laboratories, and found that the Medentis product is in fact hydrophobic (i.e.
its contact angle is clearly greater than 90°). The hydrophilic properties of
Straumann's SLActive technology enhance osseointegration and therefore shorten
healing times compared to those without hydrophilicity - as demonstrated in
preclinical and clinical investigations.1,2,3,4,5

"Dentists and patients have been misled by claims", said Dr René Willi,
Executive Vice President and Head of Straumann's Surgical Business. "Medentis
ICX-templant implants do not offer hydrophilicity, which promotes faster
healing. Faster osseointegration provides secondary stability when the implant
is placed. The court's ruling makes this clear and sends an important signal
to implant manufacturers. We are determined to take a strong, justified stand
against imitators, in the interest of patients."

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader
in implant, restorative and regenerative dentistry. In collaboration with
leading clinics, research institutes and universities, Straumann researches,
develops and manufactures dental implants, instruments, prosthetics and tissue
regeneration products for use in tooth replacement and restoration solutions
or to prevent tooth loss. Straumann currently employs approximately 2500
people worldwide and its products and services are available in more than 70
countries through its broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: investor.relations@straumann.com or
corporate.communication@straumann.com

Homepage: www.straumann.com

Contacts:

Corporate Communication:

Mark Hill

+41 (0)61 965 13 21

Thomas Konrad

+41 (0)61 965 15 46

Investor Relations:

Fabian Hildbrand

+41 (0)61 965 13 27

Straumann Media Releases subscription:

www.straumann.com/en/home/investor-relations/ir-contacts-and-services/subscription.html

RSS feed subscription:

www.straumann.com/en/home/media/media-releases.news.rss

References

1 Buser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, Hoffmann
B, Lussi A, Steinemann SG. Enhanced bone apposition to a chemically modified
SLA titanium surface. J Dent Res 2004;83:529-533.

2 Ferguson SJ, Broggini N, Wieland M, de Wild M, Rupp F, Geis-Gerstorfer J,
Cochran DL, Buser D. Biomechanical evaluation of the interfacial strength of a
chemically modified sandblasted and acid-etched titanium surface. J Biomed
Mater Res A 2006;78:291-297.

3 Schwarz F, Ferrari D, Herten M, Mihatovic I, Wieland M, Sager M, Becker J.
Effects of surface hydrophilicity and microtopography on early stages of soft
and hard tissue integration at non-submerged titanium implants: an
immunohistochemical study in dogs. J Periodontol 2007;78:2171-2184.

4 Schwarz F, Sager M, Ferrari D, Herten M, Wieland M, Becker J. Bone
regeneration in dehiscence-type defects at non-submerged and submerged
chemically modified (SLActive) and conventional SLA titanium implants: an
immunohistochemical study in dogs. J Clin Periodontol 2008;35:64-75.

5 Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early
osseointegration to hydrophilic and hydrophobic implant surfaces in humans.
Clin Oral Implants Res 2011;22:349-356.

# # #

Media release (Download)

Provider                  Channel         Contact
Tensid Ltd., Switzerland  newsbox.ch      Provider/Channel related enquiries
www.tensid.ch             www.newsbox.ch  marco@tensid.ch
                                          +41 41 763 00 50